Open AccessAlemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
Author(s) -
The CAMMS Trial Investigators
Publication year - 2008
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa0802670
Subject(s) - alemtuzumab , medicine , expanded disability status scale , hazard ratio , multiple sclerosis , interferon beta 1a , gastroenterology , confidence interval , cd52 , immunology , interferon beta , transplantation
Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom